Allogene Therapeutics, Inc. (ALLO)

NASDAQ: ALLO · Real-Time Price · USD

1.980

-0.005 (-0.25%)

At close: Sep 2, 2026, 4:00 PM EDT

1.990

+0.010 (0.51%)

Pre-market: Sep 3, 2026, 9:13 AM EDT

Allogene Therapeutics Income Statement

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Revenue	4.64	-	0.02	0.1	0.16	114.09
Revenue Growth	-	-	-76.84%	-39.10%	-99.86%	-
Cost of Revenue	122.52	150.15	192.3	242.91	256.39	220.18
Gross Profit	-117.88	-150.15	-192.28	-242.82	-256.23	-106.09
Selling, General & Admin	62.44	56.78	65.21	71.67	79.31	74.11
Operating Expenses	62.44	56.78	65.21	71.67	79.31	74.11
Operating Income	-180.32	-206.93	-257.48	-314.49	-335.54	-180.19
Interest Expense	-1.3	-1.08	-0.18	-	-	-
Interest & Investment Income	15.81	19.29	20.15	18.31	4.57	1.71
Earnings From Equity Investments	-	-	-1.69	-10.67	-12.88	-4.09
Other Non Operating Income (Expenses)	0.32	0.22	-0.28	-0.16	3.44	0.52
EBT Excluding Unusual Items	-165.49	-188.5	-239.47	-307.02	-340.41	-182.05
Gain (Loss) on Sale of Investments	-	-	-1.96	-7	-	-
Asset Writedown	-	-2.38	-15.72	-13.25	-	-
Pretax Income	-165.49	-190.89	-257.15	-327.27	-340.41	-182.05
Income Tax Expense	-	-	0.44	-	-	-
Net Income	-165.49	-190.89	-257.59	-327.27	-340.41	-182.05
Net Income to Common	-165.49	-190.89	-257.59	-327.27	-340.41	-182.05
Net Income Growth	-	-	-	-	-	-
Shares Outstanding (Basic)	254	221	195	157	143	136
Shares Outstanding (Diluted)	254	221	195	157	143	136
Shares Change	19.13%	13.25%	24.14%	9.63%	5.39%	12.84%
EPS (Basic)	-0.65	-0.87	-1.32	-2.09	-2.38	-1.34
EPS (Diluted)	-0.65	-0.87	-1.32	-2.09	-2.38	-1.34
EPS Growth	-	-	-	-	-	-

Additional Metrics

Fiscal Year	TTM	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Jun '26 Jun 30, 2026	Dec '25 Dec 31, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021
Free Cash Flow	-102.6	-149.63	-200.99	-239.25	-225.71	-206.26
Free Cash Flow Per Share	-0.40	-0.68	-1.03	-1.52	-1.58	-1.52
Gross Margin	-	-	-	-	-	-92.99%
Operating Margin	-3886.14%	-	-1170372.73%	-331044.21%	-215087.18%	-157.94%
Profit Margin	-3566.68%	-	-1170863.64%	-344489.47%	-218214.10%	-159.57%
Free Cash Flow Margin	-2211.16%	-	-913609.09%	-251841.05%	-144685.90%	-180.79%
EBITDA	-168.65	-194.57	-243.84	-300.29	-321.24	-169.74
EBITDA Margin	-	-	-	-	-	-148.78%
D&A For EBITDA	11.67	12.36	13.64	14.2	14.3	10.45
EBIT	-180.32	-206.93	-257.48	-314.49	-335.54	-180.19
EBIT Margin	-	-	-	-	-	-157.94%

SEC Filings: 10-K · 10-Q